Evidence map›Paper›PMID 40016190›Full record

ArticleNature communications2024

Integrating fragment-based screening with targeted protein degradation and genetic rescue to explore eIF4E function.

Swee Y Sharp, Marianna Martella, Sabrina D'Agostino, Christopher I Milton, George Ward, Andrew J Woodhead, Caroline J Richardson, Maria G Carr, Elisabetta Chiarparin, Benjamin D Cons and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Swee Y SharpRNA Biology and Molecular Therapeutics Team, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, SM2 5NG, UK.
Marianna MartellaRNA Biology and Molecular Therapeutics Team, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, SM2 5NG, UK.
Sabrina D'AgostinoRNA Biology and Molecular Therapeutics Team, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, SM2 5NG, UK.ORCID 0000-0002-4858-8873
Christopher I MiltonRNA Biology and Molecular Therapeutics Team, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, SM2 5NG, UK.
George WardAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.
Andrew J WoodheadAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK. Andrew.Woodhead@astx.com.ORCID 0009-0005-1604-2904
Caroline J RichardsonAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK. Caroline.Richardson@astx.com.ORCID 0000-0002-1305-4134
Maria G CarrAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.
Elisabetta ChiarparinAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.
Benjamin D ConsAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.ORCID 0000-0001-9670-6670
Joseph CoyleAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.
Charlotte E EastAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.
Steven D HiscockAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.
Carlos Martinez-FleitesAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.
Paul N MortensonAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.ORCID 0000-0002-3583-3163
Nick PalmerAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.
Puja PathuriAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.
Marissa V PowersRNA Biology and Molecular Therapeutics Team, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, SM2 5NG, UK.ORCID 0000-0003-0775-4908
Susanne M SaalauAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.ORCID 0009-0008-3130-4521
Jeffrey D St DenisAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.
Kate SwabeyRNA Biology and Molecular Therapeutics Team, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, SM2 5NG, UK.
Mladen VinkovićAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.
Hugh WaltonAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.
Glyn WilliamsAstex Pharmaceuticals, Cambridge Science Park, Cambridge, CB4 0QA, UK.
Paul A ClarkeRNA Biology and Molecular Therapeutics Team, Centre for Cancer Drug Discovery, Institute of Cancer Research, London, SM2 5NG, UK. Paul.Clarke@icr.ac.uk.ORCID 0000-0001-9342-1290

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eukaryotic initiation factor 4E (eIF4E) serves as a regulatory hub for oncogene-driven protein synthesis and is considered a promising anticancer target. Here we screen a fragment library against eIF4E and identify a ligand-binding site with previously unknown function. Follow-up structure-based design yields a low nM tool compound (4, K

Indexed as

Eukaryotic Initiation Factor-4EBinding SitesDrug DiscoveryEukaryotic Initiation Factor-4GHEK293 CellsHumansLigandsProtein BindingProtein BiosynthesisProteolysisSmall Molecule LibrariesEIF4E protein, humanEukaryotic Initiation Factor-4EEukaryotic Initiation Factor-4GLigandsSmall Molecule Libraries

Identifiers

PMID40016190
PMCPMC11868579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.